What goes up must come down: Biomarkers and novel biologicals in severe asthma

Clinical and Experimental Allergy

Volumn 45, Issue 7, 2015, Pages 1162-1169

  Hilvering, B ^a,b   Pavord, I D ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; IMMUNOGLOBULIN E ANTIBODY; MEPOLIZUMAB; OMALIZUMAB; PREDNISOLONE; PROSTAGLANDIN D2; ANTIASTHMATIC AGENT; BIOLOGICAL FACTOR; BIOLOGICAL MARKER; CYTOKINE; MONOCLONAL ANTIBODY;

AIRWAY OBSTRUCTION; ASTHMA; BLOOD; CLINICAL ASSESSMENT; CORTICOSTEROID THERAPY; DISEASE SEVERITY; EOSINOPHIL COUNT; HEALTH CARE COST; HUMAN; PHENOTYPE; PRIORITY JOURNAL; RESPIRATORY TRACT INFLAMMATION; REVIEW; TH2 CELL; ANIMAL; ANTAGONISTS AND INHIBITORS; IMMUNOLOGY; METABOLISM; MOLECULARLY TARGETED THERAPY; TREATMENT OUTCOME;

ANIMALS; ANTI-ASTHMATIC AGENTS; ANTIBODIES, MONOCLONAL; ASTHMA; BIOLOGICAL FACTORS; BIOMARKERS; CYTOKINES; HUMANS; MOLECULAR TARGETED THERAPY; PHENOTYPE; TH2 CELLS; TREATMENT OUTCOME;

EID: 84930909640     PISSN: 09547894     EISSN: 13652222     Source Type: Journal    
DOI: 10.1111/cea.12500     Document Type: Review

References (46)

1. British guideline on the management of asthma. Thorax 2008; 63(Suppl. 4):iv1-121.
2. Holgate ST, Polosa R. The mechanisms, diagnosis, and management of severe asthma in adults. Lancet 2006; 368:780-93.
3. Bateman ED, Hurd SS, Barnes PJ et al. Global strategy for asthma management and prevention: GINA executive summary. Eur Respir J 2008; 31:143-78.
4. Chung KF, Wenzel SE, Brozek JL et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J 2014; 43:343-73.
5. Jackson DJ, Sykes A, Mallia P, Johnston SL. Asthma exacerbations: origin, effect, and prevention. J Allergy Clin Immunol 2011; 128:1165-74.
6. From the Global Strategy for Asthma Management and Prevention, Global Initiative for Asthma (GINA) 2014. Available from: http://www.ginasthma.org/ (Last accessed 20 December 2014).
7. Weinberger M, Abu-Hasan M. Pseudo-asthma: when cough, wheezing, and dyspnea are not asthma. Pediatrics 2007; 120:855-64.
8. Robinson DS, Campbell DA, Durham SR, Pfeffer J, Barnes PJ, Chung KF. Systematic assessment of difficult-to-treat asthma. Eur Respir J 2003; 22:478-83.
9. Hunter CJ, Brightling CE, Woltmann G, Wardlaw AJ, Pavord ID. A comparison of the validity of different diagnostic tests in adults with asthma. Chest 2002; 121:1051-7.
10. Haldar P, Pavord ID, Shaw DE et al. Cluster analysis and clinical asthma phenotypes. Am J Respir Crit Care Med 2008; 178:218-24.
11. Green RH, Brightling CE, McKenna S et al. Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. Lancet 2002; 360:1715-21.
12. Jayaram L, Pizzichini MM, Cook RJ et al. Determining asthma treatment by monitoring sputum cell counts: effect on exacerbations. [Internet]. Eur Respir J 2006; 27:483-94.
13. Chlumsky J, Striz I, Terl M, Vondracek J. Strategy aimed at reduction of sputum eosinophils decreases exacerbation rate in patients with asthma. J Int Med Res 2006; 34:129139.
14. Licona-Limón P, Kim LK, Palm NW, Flavell RA. TH2, allergy and group 2 innate lymphoid cells. Nat Immunol 2013; 14:536-42.
15. Nath P, Leung SY, Williams AS et al. Complete inhibition of allergic airway inflammation and remodelling in quadruple IL-4/5/9/13-/- mice. Clin Exp Allergy 2007; 37:1427-35.
16. Spits H, Artis D, Colonna M et al. Innate lymphoid cells-a proposal for uniform nomenclature. Nat Rev Immunol 2013; 13:145-9.
17. Brusselle GG, Maes T, Bracke KR. Eosinophils in the spotlight: eosinophilic airway inflammation in nonallergic asthma. Nat Med 2013; 19:977-9.
18. Strunk RC, Bloomberg GR. Omalizumab for asthma. N Engl J Med 2006; 354:2689-95.
19. Normansell R, Walker S, Milan SJ, Walters EH, Nair P. Omalizumab for asthma in adults and children. Cochrane Database Syst Rev 2014; 1:CD003559.
20. Hanania NA, Wenzel S, Rosén K et al. Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study. Am J Respir Crit Care Med 2013; 187:804-11.
21. Humbert M, Busse W, Hanania NA et al. Omalizumab in asthma: an update on recent developments. J Allergy Clin Immunol Pract 2014; 2:525-536.e1.
22. Leckie MJ, ten Brinke A, Khan J et al. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet 2000; 356:2144-8.
23. Flood-Page P, Swenson C, Faiferman I et al. A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma. Am J Respir Crit Care Med 2007; 176:1062-71.
24. Flood-Page PT, Menzies-Gow AN, Kay AB, Robinson DS. Eosinophil's role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway. Am J Respir Crit Care Med 2003; 167:199-204.
25. Reddel H, Ware S, Marks G, Salome C, Jenkins C, Woolcock A. Differences between asthma exacerbations and poor asthma control. Lancet 1999; 353:364-9.
26. Pauwels RA, Löfdahl CG, Postma DS et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. N Engl J Med 1997; 337:1405-11.
27. Green RH, Brightling CE, Pavord ID, Wardlaw AJ. Management of asthma in adults: current therapy and future directions. Postgrad Med J 2003; 79:259-67.
28. Haldar P, Brightling CE, Hargadon B et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med 2009; 360:973-84.
29. Nair P, Pizzichini MMM, Kjarsgaard M et al. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. [Internet]. N Engl J Med 2009; 360:985-93.
30. Pavord ID, Korn S, Howarth P et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. [Internet]. Lancet 2012; 380:651-9.
31. Bel E, Wenzel S, Thompson P et al. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med 2014; 371:1189-97.
32. Ortega H, Liu M, Pavord I et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med 2014; 371:1198-207.
33. Castro M, Mathur S, Hargreave F et al. Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study. Am J Respir Crit Care Med 2011; 184:1125-32.
34. Busse WW, Katial R, Gossage D et al. Safety profile, pharmacokinetics, and biologic activity of MEDI-563, an anti-IL-5 receptor alpha antibody, in a phase I study of subjects with mild asthma. J Allergy Clin Immunol 2010; 125:1237-1244.e2.
35. Laviolette M, Gossage DL, Gauvreau G et al. Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia. J Allergy Clin Immunol 2013; 132:1086-1096.e5.
36. Castro M, Wenzel SE, Bleecker ER et al. Benralizumab, an anti-interleukin 5 receptor α monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study. Lancet Respir Med 2014; 2:879-90.
37. Brightling CE, Bleecker ER, Panettieri RA et al. Benralizumab for chronic obstructive pulmonary disease and sputum eosinophilia: a randomised, double-blind, placebo-controlled, phase 2a study. Lancet Respir Med 2014; 2:891-901.
38. Gauvreau G, Boulet L-P, Cockcroft D et al. Effects of interleukin-13 blockade on allergen-induced airway responses in mild atopic asthma. Am J Respir Crit Care Med 2011; 183:1007-14.
39. Corren J, Lemanske RF, Hanania NA et al. Lebrikizumab treatment in adults with asthma. [Internet]. N Engl J Med 2011; 365:1088-98.
40. Piper E, Brightling C, Niven R et al. A phase II placebo-controlled study of tralokinumab in moderate-to-severe asthma. Eur Respir J 2012; 365:1088-98.
41. Boever E, Ashman C, Cahn A et al. Efficacy and safety of an anti-IL-13 mAb in patients with severe asthma: a randomized trial. J Allergy Clin Immunol 2014; 133:989996.e4.
42. Corren J, Busse W, Meltzer E et al. A randomized, controlled, phase 2 study of AMG 317, an IL-4Ralpha antagonist, in patients with asthma. Am J Respir Crit Care Med 2010; 181:788-96.
43. Wenzel S, Ford L, Pearlman D et al. Dupilumab in persistent asthma with elevated eosinophil levels. N Engl J Med 2013; 368:2455-66, DOI: 10.1056/NEJMoa1304048.
44. Nair P, Gaga M, Zervas E et al. Safety and efficacy of a CXCR2 antagonist in patients with severe asthma and sputum neutrophils: a randomized, placebo-controlled clinical trial. Clin Exp Allergy 2012; 42:1097-103.
45. Chesné J, Braza F, Mahay G, Brouard S, Aronica M, Magnan A. IL-17 in severe asthma: where do we stand? Am J Respir Crit Care Med 2014; 190:1094-101.
46. Busse WW, Holgate S, Kerwin E et al. Randomized, double-blind, placebo-controlled study of brodalumab, a human anti-IL-17 receptor monoclonal antibody, in moderate to severe asthma. Am J Respir Crit Care Med 2013; 188:1294-302.